Payment overview · 2025
General Payments
$640.12
33 reported records · 15 companies
Healthcare provider profile · identity verified
James W Hall, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · KANSAS CITY, MO · NPI 1295735504
Verified facts
What the public records show
CMS Open Payments records show James W Hall, M.D. received $640.12 in general payments during 2025 across 33 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $146.68 | 22.9% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $74.21 | 11.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.74 | 11.4% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $68.15 | 10.7% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $62.76 | 9.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.66 | 5.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $29.57 | 4.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.23 | 4.6% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $20.77 | 3.2% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $18.94 | 3.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 2.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.51 | 2.7% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $16.42 | 2.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.97 | 2.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.66 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $640.12 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $95.87 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $80.50 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $72.74 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $68.15 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $66.50 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $62.76 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.15 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.09 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.06 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.06 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.66 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.66 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $29.57 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 50 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 114 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 129 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
114 | 33 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
203 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
114 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
129 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 696 | 208 |
| Omeprazole | Omeprazole | 673 | 198 |
| Atorvastatin Calcium | Atorvastatin Calcium | 642 | 167 |
| Losartan Potassium | Losartan Potassium | 540 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 405 | 109 |
| Lisinopril | Lisinopril | 331 | 97 |
| Metformin Hcl | Metformin Hcl | 311 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 293 | 84 |
| Hydrochlorothiazide | Hydrochlorothiazide | 284 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 279 | 81 |
| Carvedilol | Carvedilol | 228 | 58 |
| Eliquis | Apixaban | 203 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 201 | 50 |
| Furosemide | Furosemide | 195 | 61 |
| Simvastatin | Simvastatin | 182 | 50 |
| Tramadol Hcl | Tramadol Hcl | 175 | 40 |
| Allopurinol | Allopurinol | 154 | 47 |
| Ezetimibe | Ezetimibe | 153 | 48 |
| Meloxicam | Meloxicam | 147 | 55 |
| Prednisone | Prednisone | 145 | 99 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 133 | 39 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 130 | 130 |
| Ozempic | Semaglutide | 129 | 21 |
| Jardiance | Empagliflozin | 114 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 32 |
| Alprazolam | Alprazolam | 103 | 24 |
| Trazodone Hcl | Trazodone Hcl | 103 | 31 |
| Ibandronate Sodium | Ibandronate Sodium | 102 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 35 |
| Atenolol | Atenolol | 82 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 24 |
| Finasteride | Finasteride | 79 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 26 |
| Fenofibrate | Fenofibrate | 73 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 71 | 30 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 70 | 58 |
| Naproxen | Naproxen | 66 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 14 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 63 | 63 |
| Warfarin Sodium | Warfarin Sodium | 59 | suppressed |
| Spironolactone | Spironolactone | 57 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 42 |
| Gabapentin | Gabapentin | 55 | 17 |
| Raloxifene Hcl | Raloxifene Hcl | 55 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 19 |
| Montelukast Sodium | Montelukast Sodium | 52 | 16 |
| Farxiga | Dapagliflozin Propanediol | 50 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 50 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 48 | 38 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | suppressed |
| Potassium Chloride | Potassium Chloride | 45 | 15 |
| Propranolol Hcl | Propranolol Hcl | 45 | 13 |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 44 | 14 |
| Nitroglycerin | Nitroglycerin | 42 | 26 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 12 |
| Amoxicillin | Amoxicillin | 38 | 33 |
| Imiquimod | Imiquimod | 37 | 19 |
| Xarelto | Rivaroxaban | 37 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 34 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 12 |
| Glipizide | Glipizide | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Estradiol | Estradiol | 32 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 17 |
| Oxycontin | Oxycodone Hcl | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Colchicine | Colchicine | 17 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Irbesartan | Irbesartan | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $640.12 · 33 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CAMZYOS, FARXIGA, FREESTYLE LIBRE 3, Flector, JARDIANCE, Kerendia, Leqembi, Licart, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, Tirosint, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XYOSTED, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error